These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 11225517)

  • 21. [Effect of selegiline against selective neurotoxins].
    Magyar K
    Vopr Med Khim; 1997; 43(6):504-14. PubMed ID: 9503567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
    Kan JP; Steinberg R; Mouget-Goniot C; Worms P; Bizière K
    J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P; Youdim MB
    J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency.
    Yoshida T; Yamada Y; Yamamoto T; Kuroiwa Y
    Xenobiotica; 1986 Feb; 16(2):129-36. PubMed ID: 3083608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain.
    Waldmeier PC; Baumann PA
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(1):20-6. PubMed ID: 6195533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.
    Kumagae Y; Matsui Y; Iwata N
    Jpn J Pharmacol; 1991 Jan; 55(1):121-8. PubMed ID: 1904113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "In vitro" effect of some 5-hydroxy-indolalkylamine derivatives on monoamine uptake system.
    Morón JA; Perez V; Fernández-Alvarez E; Marco JL; Unzeta M
    J Neural Transm Suppl; 1998; 52():343-9. PubMed ID: 9564637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Analysis of the Neurochemical Profile and MAO Inhibition Properties of N-(Furan-2-ylmethyl)-N-methylprop-2-yn-1-amine.
    De Deurwaerdère P; Binda C; Corne R; Leone C; Valeri A; Valoti M; Ramsay RR; Fall Y; Marco-Contelles J
    ACS Chem Neurosci; 2017 May; 8(5):1026-1035. PubMed ID: 27977122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modification of dopamine release by selective inhibitors of MAO-B.
    Finberg JP; Lamensdorf I; Armoni T
    Neurobiology (Bp); 2000; 8(2):137-42. PubMed ID: 11061211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of co-administration of antidepressants and monoamine oxidase inhibitors on 5-HT-related behavior in rats.
    Izumi T; Iwamoto N; Kitaichi Y; Kato A; Inoue T; Koyama T
    Eur J Pharmacol; 2007 Jun; 565(1-3):105-12. PubMed ID: 17400208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac).
    Leonardi ET; Azmitia EC
    Neuropsychopharmacology; 1994 Jul; 10(4):231-8. PubMed ID: 7945733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake.
    Fang J; Yu PH
    Neuropharmacology; 1994 Jun; 33(6):763-8. PubMed ID: 7936114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K; Szende B
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of monoamine oxidase inhibitors on methamphetamine-induced stereotypy in mice and rats.
    Tatsuta T; Kitanaka N; Kitanaka J; Morita Y; Takemura M
    Neurochem Res; 2005 Nov; 30(11):1377-85. PubMed ID: 16341934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperserotonergic phenotype after monoamine oxidase inhibition in larval zebrafish.
    Sallinen V; Sundvik M; Reenilä I; Peitsaro N; Khrustalyov D; Anichtchik O; Toleikyte G; Kaslin J; Panula P
    J Neurochem; 2009 Apr; 109(2):403-15. PubMed ID: 19222706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area.
    Chenu F; El Mansari M; Blier P
    Int J Neuropsychopharmacol; 2009 May; 12(4):475-85. PubMed ID: 18700056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor.
    Hewton R; Salem A; Irvine RJ
    Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):1051-7. PubMed ID: 17714093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic L-deprenyl treatment alters brain monoamine levels and reduces impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder.
    Boix F; Qiao SW; Kolpus T; Sagvolden T
    Behav Brain Res; 1998 Jul; 94(1):153-62. PubMed ID: 9708846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines.
    Yang HY; Neff NH
    J Pharmacol Exp Ther; 1974 Jun; 189(3):733-40. PubMed ID: 4843170
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.